Trading in AstraZeneca's (AZN 2.26%) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange. Investors clearly liked that idea, as they bid those ADSes up by more than 2% that trading session. With that rise, it did better than the S&P 500 (^GSPC -0.11%), which closed the day marginally (0.1%) lower.Bye-bye Britain?That morning, U.K. newspaper The Times published an article stating that AstraZeneca CEO Pascal Soriot aims to ...